文献速递免疫规划传染病防控与疫情报告

第三剂疫苗使异源或同源COVID-19疫苗方案的有效性和免疫原性水平趋于一致,法国里昂,2021年12月至2022年3月

A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022.
PubMed 文献 · Euro Surveill · 2023-01-01

在法国里昂大学医院接种疫苗的医护人员中,结合观察性流行病学与前瞻性队列研究分析第三剂mRNA疫苗前后的免疫学参数。第二剂后异源方案对感染的保护优于同源方案(校正HR=1.88;95%CI:1.18-3.00;p=0.008),第三剂后此优势消失(校正HR=0.86;95%CI:0.72-1.02;p=0.082)。同源组第三剂后受体结合域特异性IgG水平和血清中和能力高于第二剂后,异源组则无此变化。

要点

  • 第二剂后异源方案保护优于同源方案(校正HR=1.88;95%CI:1.18-3.00;p=0.008)。
  • 第三剂后异源与同源方案保护无显著差异(校正HR=0.86;95%CI:0.72-1.02;p=0.082)。
  • 同源组第三剂后IgG和中和能力高于第二剂后,异源组无此升高。

核心结论

  • 异源疫苗接种在第三剂后于保护和免疫原性方面的优势均消失。
  • 接种后1个月的免疫学测量提示异源方案在第二剂后即诱导最大免疫,而同源方案个体需第三剂才能达到相同水平。

研究设计与样本

  • 结合法国里昂大学医院接种疫苗医护人员中SARS-CoV-2感染的观察性流行病学研究与前瞻性队列研究,分析第三剂mRNA疫苗前后免疫学参数。

主要发现

  • 第二剂后异源方案较同源方案更防感染(校正HR=1.88;95%CI:1.18-3.00;p=0.008)。
  • 第三剂后异源与同源方案保护无显著差异(校正HR=0.86;95%CI:0.72-1.02;p=0.082)。
  • 同源组第三剂后受体结合域特异性IgG水平和针对不同SARS-CoV-2变异株的血清中和能力高于第二剂后,异源组则无。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundTo cope with the persistence of the COVID-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially for the primary vaccination course, and the heterologous Vaxzevria/Comirnaty regimen had shown better efficacy and immunogenicity than the homologous Comirnaty/Comirnaty regimen.AimWe wanted to determine if this benefit was retained after a third dose of an mRNA vaccine.MethodsWe combined an observational epidemiological study of SARS-CoV-2 infections among vaccinated healthcare workers at the University Hospital of Lyon, France, with a prospective cohort study to analyse immunological parameters before and after the third mRNA vaccine dose.ResultsFollowing the second vaccine dose, heterologous vaccination regimens were more protective against infection than homologous regimens (adjusted hazard ratio (HR) = 1.88; 95% confidence interval (CI): 1.18-3.00; p = 0.008), but this was no longer the case after the third dose (adjusted HR = 0.86; 95% CI: 0.72-1.02; p = 0.082). Receptor-binding domain-specific IgG levels and serum neutralisation capacity against different SARS-CoV-2 variants were higher after the third dose than after the second dose in the homologous regimen group, but not in the heterologous group.ConclusionThe advantage conferred by heterologous vaccination was lost after the third dose in terms of both protection and immunogenicity. Immunological measurements 1 month after vaccination suggest that heterologous vaccination induces maximal immunity after the second dose, whereas the third dose is required to reach the same level in individuals with a homologous regimen.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Guibert N, Trepat K, Pozzetto B, et al. A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022. Euro Surveill. 2023. PMID: 37052679. doi:10.2807/1560-7917.ES.2023.28.15.2200746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。